You spoke and we listened!
In 2025, we will be piloting changes to our scheme portfolio to enable more flexibility when participating in EQA.
New for 2025, the hereditary hearing loss scheme has options to participate in EQA for either targeted DFNB1 locus testing, or for gene panel testing, enabling you to choose the format that best aligns with your laboratory requirements.
Some EQA schemes include the option to purchase extra cases. For example, the lung cancer (NSCLC) EQA scheme is available for laboratories providing testing services for common biomarkers in EGFR, KRAS and BRAF, and has the option to add on extra cases for new and emerging biomarkers involving the EGFR, KRAS, ERRB2 and MET genes.
If successful, we will roll these strategies more widely in 2026. We aim to better meet the needs of laboratories as the genetic testing landscape continues to evolve by offering more flexibility in the EQA services we provide.
Our goal is to ensure the highest diagnostic quality, from laboratory to patient.
Feel free to explore our website further, and subscribe to our newsletter to stay up to date on where we’re going next.
